See more : Castlight Health, Inc. (CSLT) Income Statement Analysis – Financial Results
Complete financial analysis of LadRx Corporation (CYTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LadRx Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Wilmar International Limited (WLMIF) Income Statement Analysis – Financial Results
- Sunita Tools Limited (SUNITATOOL.BO) Income Statement Analysis – Financial Results
- Manoj Vaibhav Gems ‘N’ Jewellers Limited (MVGJL.BO) Income Statement Analysis – Financial Results
- Stria Lithium Inc. (SRCAF) Income Statement Analysis – Financial Results
- Tradehold Limited (TDH.JO) Income Statement Analysis – Financial Results
LadRx Corporation (CYTR)
About LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 100.00K | 200.00K | 100.00K | 100.00K | 300.00K | 100.00K | 250.00K | 100.00K | 9.50M | 6.27M | 7.46M | 2.07M | 184.36K | 428.16K | 94.00K | 1.34M | 4.40M | 3.33M | 823.00K | 1.30M | 14.30M | 2.90M | 2.50M | 2.50M | 4.50M | 2.50M | 4.80M | 1.10M | 500.00K | 900.00K | 700.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.29K | 70.50K | -49.94K | 217.00K | -300.00K | 6.40M | 1.60M | 800.00K | -300.00K | -100.00K | 0.00 | 0.00 | 700.00K | 2.20M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 100.00K | 200.00K | 100.00K | 100.00K | 300.00K | 100.00K | 250.00K | 100.00K | 9.50M | 6.27M | 7.46M | 2.07M | 184.36K | 428.16K | 94.00K | 1.33M | 4.33M | 3.38M | 606.00K | 1.60M | 7.90M | 1.30M | 1.70M | 2.80M | 4.60M | 2.50M | 4.80M | 400.00K | -1.70M | 900.00K | 700.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.16% | 98.40% | 101.50% | 73.63% | 123.08% | 55.24% | 44.83% | 68.00% | 112.00% | 102.22% | 100.00% | 100.00% | 36.36% | -340.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 799.58K | 403.01K | 388.84K | 19.84M | 35.93M | 43.40M | 36.68M | 17.50M | 12.68M | 15.49M | 8.51M | 7.54M | 10.47M | 18.82M | 9.78M | 9.09M | 6.01M | 4.39M | 767.10K | 1.84M | 1.96M | 12.81M | 7.30M | 5.60M | 3.10M | 7.10M | 6.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.55B | 5.97M | 6.00M | 7.44M | 8.08M | 12.50M | 15.99M | 19.67M | 12.85M | 10.27M | 8.35M | 7.32B | 8.24B | 9.13B | 10.93B | 14.82B | 9.66B | 366.75M | 0.00 | 0.00 | 0.00 | 3.42M | 2.25M | 3.78M | 2.50M | 8.80M | 4.50M | 3.50M | 3.50M | 7.70M | 5.00M | 2.50M | 1.30M | 2.10M | 6.00M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.31B | -8.23B | -9.12B | -10.92B | -14.81B | -9.65B | -360.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.55B | 5.97M | 6.00M | 7.44M | 8.08M | 12.50M | 15.99M | 19.67M | 12.85M | 10.27M | 8.35M | 7.32M | 8.24M | 9.13M | 10.93M | 14.82M | 9.66M | 6.42M | 7.90M | 6.99M | 3.88M | 3.42M | 2.25M | 3.78M | 2.50M | 8.80M | 4.50M | 3.50M | 3.50M | 7.70M | 5.00M | 2.50M | 1.30M | 2.10M | 6.00M | 3.50M |
| Other Expenses | 15.00M | 13.98K | 29.04K | 20.66K | 29.42K | 629.31K | 536.63K | 317.65K | 182.93K | 120.40K | 113.94K | 95.52K | 107.67K | 475.32K | 624.98K | 272.23K | 227.70K | 217.10K | 103.85K | 2.13K | 1.13M | 0.00 | 317.85K | 68.00K | 500.00K | 800.00K | 700.00K | 600.00K | 400.00K | 200.00K | 100.00K | 100.00K | 100.00K | 500.00K | 600.00K | 300.00K |
| Operating Expenses | 4.56B | 5.98M | 6.83M | 7.86M | 8.50M | 32.97M | 52.46M | 63.38M | 49.71M | 27.89M | 21.15M | 22.90M | 16.85M | 17.15M | 22.02M | 33.92M | 19.67M | 15.73M | 14.02M | 11.38M | 5.78M | 5.26M | 4.53M | 16.66M | 10.30M | 15.20M | 8.30M | 11.20M | 10.70M | 7.90M | 5.10M | 2.60M | 1.40M | 2.60M | 6.60M | 3.80M |
| Cost & Expenses | 4.56B | 5.98M | 6.83M | 7.86M | 8.50M | 32.97M | 52.46M | 63.38M | 49.71M | 27.89M | 21.15M | 22.90M | 16.85M | 17.15M | 22.02M | 33.92M | 19.67M | 15.73M | 14.02M | 11.38M | 5.79M | 5.33M | 4.48M | 16.88M | 10.00M | 21.60M | 9.90M | 12.00M | 10.40M | 7.80M | 5.10M | 2.60M | 2.10M | 4.80M | 6.60M | 3.80M |
| Interest Income | 11.69M | 16.82K | 119.27K | 351.97K | 355.56K | 365.58K | 255.12K | 233.96K | 305.33K | 137.68K | 131.67K | 207.22K | 303.59K | 349.49K | 1.20M | 0.00 | 996.65K | 206.20K | 59.98M | 82.06K | 95.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 201.07M | 16.82K | 0.00 | 0.00 | 1.72M | 3.83M | 2.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00M | 13.98K | 230.14K | 20.66K | 29.42K | 629.31K | 536.63K | 317.65K | 182.93K | 120.40K | 113.94K | 95.52K | 107.67K | 475.32K | 624.98K | 272.23K | 227.70K | 217.10K | 103.85K | 2.13K | 1.13M | 586.25K | 317.85K | 68.00K | 500.00K | 800.00K | 700.00K | 600.00K | 400.00K | 200.00K | 100.00K | 100.00K | 100.00K | 500.00K | 600.00K | 300.00K |
| EBITDA | -4.55B | -13.15M | -6.47M | -7.14M | -10.97M | -30.53M | -47.48M | -58.27M | -29.93M | -47.36M | -17.85M | -14.23M | 516.13K | -4.84M | -25.55M | -21.58M | -16.38M | -14.88M | -16.29M | 2.13M | -5.05M | -345.09K | -30.25K | -14.97M | -5.80M | -5.20M | -5.10M | -10.10M | -7.30M | -3.00M | -2.40M | 2.60M | -800.00K | -4.30M | -4.10M | -1.80M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4,387.06% | -30,525.11% | -23,739.56% | -58,268.74% | -29,934.25% | -15,787.81% | -17,848.34% | -5,692.41% | 516.13% | -50.99% | -407.72% | -289.28% | -792.91% | -8,068.87% | -3,804.23% | -18,981.35% | -376.11% | -7.84% | -0.91% | -1,819.32% | -446.15% | -36.36% | -175.86% | -404.00% | -292.00% | -66.67% | -96.00% | 54.17% | -72.73% | -860.00% | -455.56% | -257.14% |
| Operating Income | -4.56B | -13.16M | -6.83M | -7.86M | -8.25M | -32.87M | -52.26M | -63.28M | -49.61M | -27.59M | -21.05M | -22.65M | -16.75M | -7.64M | -23.77M | -26.46M | -17.60M | -15.54M | -16.61M | -11.28M | -4.45M | -931.34K | -1.15M | -16.06M | -8.70M | -7.30M | -7.00M | -9.50M | -7.90M | -3.30M | -2.60M | 2.20M | -1.00M | -4.30M | -5.70M | -3.10M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3,299.31% | -32,871.42% | -26,128.92% | -63,278.22% | -49,605.63% | -9,198.15% | -21,051.73% | -9,061.59% | -16,750.60% | -80.47% | -379.33% | -354.73% | -852.02% | -8,431.39% | -3,879.77% | -12,004.68% | -331.42% | -21.17% | -34.48% | -1,951.15% | -669.23% | -51.05% | -241.38% | -380.00% | -316.00% | -73.33% | -104.00% | 45.83% | -90.91% | -860.00% | -633.33% | -442.86% |
| Total Other Income/Expenses | -201.07M | -16.82K | 129.35K | 339.64K | -830.34K | -2.11M | 1.49M | 4.69M | 19.49M | -19.89M | 3.09M | 8.33M | 17.16M | 2.33M | -2.40M | 4.61M | 993.44K | -15.08B | -16.38B | -17.83B | -6.17B | 0.00 | 0.00 | 1.07M | 1.20M | 1.40M | 1.20M | -1.10M | 0.00 | 0.00 | 2.40M | 300.00K | 100.00K | 0.00 | 300.00K | 900.00K |
| Income Before Tax | -4.76B | -13.18M | -6.70M | -7.52M | -9.08M | -34.99M | -50.77M | -58.59M | -30.12M | -47.48M | -17.96M | -14.33M | 408.46K | -5.32M | -26.17M | -21.85M | -16.61M | -15.09B | -16.39B | -17.84B | -6.18B | -931.34K | 0.00 | -14.99M | -7.50M | -5.90M | -5.80M | -10.60M | 0.00 | 0.00 | -200.00K | 2.50M | -900.00K | 0.00 | -5.40M | -2.20M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -3,631.44% | -34,985.63% | -25,385.21% | -58,586.39% | -30,117.18% | -15,827.95% | -17,962.27% | -5,730.62% | 408.46% | -55.99% | -417.69% | -292.93% | -803.93% | -8,186,624.00% | -3,828,483.71% | -18,983,617.02% | -460,212.73% | -21.17% | 0.00% | -1,821.26% | -576.92% | -41.26% | -200.00% | -424.00% | 0.00% | 0.00% | -8.00% | 52.08% | -81.82% | 0.00% | -600.00% | -314.29% |
| Income Tax Expense | 201.07M | 16.82K | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | 1.60K | 1.60K | 98.00K | 17.16M | -519.16K | 873.00K | 40.00K | 145.00K | 163.60K | -3.02M | -6.66M | -1.73M | 0.00 | 0.00 | 1.07M | 1.20M | 1.40M | 1.20M | -1.10M | 0.00 | 0.00 | 0.00 | 300.00K | 100.00K | 0.00 | 300.00K | 900.00K |
| Net Income | -4.96B | -13.19M | -6.70M | -7.16M | -12.71M | -34.99M | -50.77M | -58.59M | -30.12M | -47.49M | -17.96M | -14.42M | 408.46K | -4.80M | -27.05M | -21.89M | -16.75M | -15.09M | -16.39M | -17.84M | -6.18M | -931.34K | -348.10K | -15.04M | -6.30M | -6.00M | -5.80M | -10.70M | -7.70M | -3.20M | -100.00K | 2.50M | -900.00K | -4.80M | -4.70M | -2.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -5,085.44% | -34,986.43% | -25,385.61% | -58,587.19% | -30,117.98% | -15,828.48% | -17,963.87% | -5,769.82% | 408.46% | -50.53% | -431.62% | -293.47% | -810.95% | -8,186.62% | -3,828.48% | -18,983.62% | -460.21% | -21.17% | -10.46% | -1,827.58% | -484.62% | -41.96% | -200.00% | -428.00% | -308.00% | -71.11% | -4.00% | 52.08% | -81.82% | -960.00% | -522.22% | -300.00% |
| EPS | -114.46 | -0.35 | -0.19 | -0.22 | -0.41 | -1.46 | -3.76 | -5.81 | -3.32 | -8.66 | -4.69 | -4.83 | 0.16 | -2.02 | -12.43 | -10.94 | -10.33 | -11.15 | -20.06 | -27.43 | -16.21 | -3.78 | -1.55 | -82.55 | -34.70 | -33.94 | -31.50 | -56.70 | -39.48 | -17.22 | -0.56 | 20.16 | -8.40 | -47.04 | -48.72 | -16.80 |
| EPS Diluted | -114.46 | -0.35 | -0.19 | -0.22 | -0.41 | -1.46 | -3.76 | -5.81 | -3.32 | -8.66 | -4.69 | -4.83 | 0.15 | -2.02 | -12.43 | -10.94 | -10.33 | -11.15 | -20.06 | -27.43 | -16.21 | -3.78 | -1.55 | -82.55 | -33.08 | -33.94 | -31.50 | -55.79 | -39.48 | -17.22 | -0.56 | 20.16 | -8.40 | -47.04 | -48.72 | -16.80 |
| Weighted Avg Shares Out | 43.36M | 37.58M | 34.65M | 33.26M | 30.95M | 24.04M | 13.51M | 10.08M | 9.06M | 5.48M | 3.83M | 2.99M | 2.61M | 2.38M | 2.18M | 2.00M | 1.62M | 1.35M | 817.28K | 650.59K | 381.05K | 246.63K | 224.38K | 182.20K | 181.56K | 176.77K | 184.13K | 188.71K | 195.04K | 185.83K | 178.57K | 124.01K | 107.14K | 102.04K | 96.47K | 125.00K |
| Weighted Avg Shares Out (Dil) | 43.36M | 37.58M | 34.65M | 33.26M | 30.95M | 24.04M | 13.51M | 10.08M | 9.06M | 5.48M | 3.83M | 2.99M | 2.65M | 2.38M | 2.18M | 2.00M | 1.62M | 1.35M | 817.28K | 650.59K | 381.05K | 246.63K | 224.38K | 182.20K | 190.48K | 176.77K | 184.13K | 191.80K | 195.04K | 185.83K | 178.57K | 124.01K | 107.14K | 102.04K | 96.47K | 125.00K |
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
LOS ANGELES--(BUSINESS WIRE)--LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to announce that the Company and NantCell, Inc. (“NantCell”), together with NantCell's parent company ImmunityBio, Inc....
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information...
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA) (NASDAQ:ORPH) (“Orphazyme”) has submitted a Marketing Authorisation Application...
Source: https://incomestatements.info
Category: Stock Reports